Drugs / Zelpultide alfa
Zelpultide alfa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04662151 | Sep 2021 → Aug 2023 | bronchopulmonary dysplasia | Airway Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04659122 | Aug 2021 → Feb 2023 | COVID-19 | Airway Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06897839 | Feb 2025 → Mar 2028 expected | bronchopulmonary dysplasia | Airway Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-28 | Airway Therapeutics, Inc. | Regulatory Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa’s Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants airwaytherapeutics.com ↗ |
| 2024-06-24 | Airway Therapeutics, Inc. | Results Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia airwaytherapeutics.com ↗
No dose limiting toxicities were found while indications of efficacy were observed. |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zelpultide alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06897839 ↗ |
| Known as | AT-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04659122 ↗ |
| Known as | Recombinant sp-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650375 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human surfactant protein D” PMID 41018057 ↗ Sep 2025 |
| Route | Other | “intratracheal administration” NCT04659122 ↗ |